Skip to main content
. 2021 Jan 27;13(2):391. doi: 10.3390/nu13020391

Figure 3.

Figure 3

Prevalence of subjects with CRP ≥ 0.8 mg/L at t0 (baseline), t1 (60 days after enrollment) and t2 (90 days after enrollment) among subjects who did not register clinical manifestations of infection throughout the study—intervention group (Proxian®) and controls (placebo).